Illumina Accelerator, which is accepting applications for its seventh funding cycle, operates six-month programs during which selected startups receive business guidance, seed investment and access to Illumina’s software and lab space.
Through the agreement with Helix, a personal genomics company, selected startups will be able to build their products on Helix’s next generation sequencing platform and have access to the company’s team of leadership experts for guidance related to applied genomics, regulatory affairs and consumer marketing.
“From an entrepreneur’s perspective, cost pressures, stringent regulatory and data security requirements and continually evolving sequencing technologies are barriers to designing, developing, scaling up and commercializing DNA-powered products for everyday life,” said Robin Thurston, CEO of Helix.
Applications for Illumina Accelerator’s seventh funding cycle are due Sept. 1.
More articles on data analytics & precision medicine:
Startup Insider: 4 questions with 2bPrecise CEO Assaf Halevy
Mass General, UC San Diego to use IBM’s World Community Grid for microbiome study
Novartis builds study on Apple ResearchKit to investigate multiple sclerosis
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.